Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lorcaserin Re-Review Expected To Address Risk/Benefit Trade-offs, Rat Tumors

16 Mar 2012

• By Emily Hayes

Related Content

Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin

04 Jan 2012

Advisory Committee Set To Review Cardiovascular Risk Assessment For Obesity Drugs

07 Feb 2012

Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden

27 Feb 2012

Arena Must Deal With Rat Neoplasms To Move Forward With <i>Lorqess</i>

20 Sep 2010

Orexigen Agreement On <i>Contrave</i> CV Trial Hints At FDA’s Thinking On Obesity

26 Sep 2011

Related Companies

Arena Pharmaceuticals, Inc.

Eisai Co., Ltd.

Vivus, Inc.

Orexigen Therapeutics, Inc.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.